Alexandra "Ally" Funk, PharmD, DABAT, FAACT

Nomination for Re-Election of AACT Board of Trustees, Trustee

Current Position:

Director, Florida Poison Information Center - Tampa

AACT and AACT-related activities, including ABAT

- AACT Board of Trustee
 - September 2020 Present
- AACT Fellow
 - September 2024
- AACT Pre Symposium Speaker, NACCT 2024
 - "It's All Supportive Care, IV Fluids & Dextrose"
- AACT DEI Section
 - Section Co-Chair, April 2022 Present
 - Task Force Co-Chair, June 2021 April 2022
- AACT Antidote Collective
 - Physostigmine Member, December 2023 Present
- AACT Membership Committee
 - Chair, March 2025 Present
 - Member & Board Liaison, June 2022 March 2025
- ABAT/AACT Webinar Committee
 - o Co-Coordinator & Moderator, November 2018 November 2024
- ABAT Members as Poison Center Directors Committee
 - o Member, December 2023 Present
- ABAT Exam Question Committee
 - o Member, December 2022 Present
- ABAT Credentialing Committee
 - Member, June 2020 Present

Non-AACT, Toxicology Related Leadership Experience

- America's Poison Center (APC) Joint Micromedex Coding Committee

 Member, September 2022 Present
- APC Rapid Coding Committee
 - Member, September 2022 Present
- APC Acetaminophen Guideline Consensus Panel
 - Member, January 2022 Present
- APC Midyear Meeting Planning Committee
 - Co-Chair, December 2021 April 2023
 - Member, December 2019 December 2021



- APC NPDS Toxicosurveillance Team
 - Member & Anomaly Reviewer, November 2019 Present
- APC Fatality Review Committee,
 - o Reviewer, December 2016 December 2021

Biography:

I am the Director of the Florida Poison Information Center - Tampa at Tampa General Hospital and have been in Poison Center management since 2019. As the Poison Center Director I am responsible for all administrative, financial, and personnel duties. I work closely alongside the Medical Directors performing clinical duties and providing patient care. Additionally, I serve as the primary preceptor for pharmacy students and residents, and co-precept medical students, residents, and fellows. In April, I was appointed Assistant Professor in the University of South Florida, Morsani College of Medicine Emergency Medicine Department, as our Poison Center and Medical Toxicology group begin to establish a Medical Toxicology Fellowship program.

I completed my PharmD training at D'Youville University School of Pharmacy in 2015, followed by a PGY1 Pharmacy Practice Residency at AdventHealth Orlando, and a Clinical Toxicology Fellowship at the Georgia Poison Center. I achieved the status of Diplomate of the American Board of Applied Toxicology (DABAT) in 2017 and Fellow Status for the American Academy of Clinical Toxicology (AACT) in 2024.

Personal Statement:

I first want to thank the members of the AACT for my nomination and the opportunity to previously serve on the Board of Trustees (BOT). It has been a sincere privilege to serve in this capacity. I am deeply grateful to the Academy for the opportunity to advocate on behalf of our members and contribute to the continued advancement of clinical toxicology.

From my initial introduction to the field of toxicology, I have found the AACT to be an inspiring and distinguished organization. Over the course of my years of involvement, I have had the honor of serving in roles that span education, quality assurance, planning, surveillance, and recruitment through various AACT, ABAT, and APC committee efforts and initiatives.

During my current term on the Board of Trustees, I have been proud to lead and participate in several key initiatives, including:

• Fellows-in-Training Inclusion: I proposed and helped implement the inclusion of fellows-in-training (FIT) within AACT, resulting in the creation of board positions specifically for medical and clinical toxicology fellows. This

initiative has laid the foundation for greater engagement, mentorship, and professional development of emerging toxicologists. The AACT BOT has welcomed their first two inaugural FIT BOT members who have made an invaluable contribution focusing on initiatives that support those FITs and junior faculty and will continue this initiative moving forward.

• Guiding the DEI Section Through Transitions: I remained steadfast in guiding the Diversity, Equity, and Inclusion Section through a period of organizational transition. Despite challenges, we preserved and promoted the section's core mission: fostering an inclusive environment, ensuring diverse voices are heard, and supporting knowledge sharing across our membership. This work was carried out with professionalism, thoughtfulness, and respect for the evolving landscape, ensuring alignment with AACT's values, vision, and member's needs.

• **Management Transition Support:** I contributed to the successful transition to a new management company, an important milestone for AACT. This change positions our organization for long-term stability, increased responsiveness, and continued growth. It was a collaborative process grounded in transparency and a shared commitment to the future of our Academy.

If re-elected to serve another term, I will continue to champion initiatives that cultivate collaboration, inclusion, professional development, and organizational growth.

Specifically, I will:

• Strengthen mentorship and engagement opportunities for ALL members, inclusive of early-career toxicologists, such as encouraging members to share their needs via open dialogue and expanding fellow-in-training and member involvement in various initiatives.

• Support transparent, mission-aligned governance and operational improvements to ensure AACT remains adaptable and member-focused.

• Foster collaborative relationships within and outside the AACT to amplify the voice and value of clinical toxicology in public health, education, and healthcare systems.

The future of our field of clinical toxicology lies in the hands of our organization. I am committed to ensuring that all members, regardless of background, discipline, or career stage, have access to meaningful opportunities to contribute and thrive.

Thank you for your time and consideration. I would be honored to continue serving our Academy through another term as a Board of Trustee and contributing to its mission of advancing the science and practice of clinical toxicology.

Sincerely,

Alexander Fine

Alexandra "Ally" Funk, PharmD, DABAT, FAACT